Cargando…
European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 2: flunarizine
OBJECTIVE: Novel disease-specific and mechanism-based treatments sharing good evidence of efficacy for migraine have been recently marketed. However, reimbursement by insurers depends on treatment failure with classic anti-migraine drugs. In this systematic review and meta-analysis, we aimed to iden...
Autores principales: | Deligianni, Christina I., Sacco, Simona, Ekizoglu, Esme, Uluduz, Derya, Gil-Gouveia, Raquel, MaassenVanDenBrink, Antoinette, Ornello, Raffaele, Sanchez-del-Rio, Margarita, Reuter, Uwe, Versijpt, Jan, de Vries, Tessa, Hussain, Muizz, Zeraatkar, Dena, Lampl, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507915/ https://www.ncbi.nlm.nih.gov/pubmed/37723437 http://dx.doi.org/10.1186/s10194-023-01657-3 |
Ejemplares similares
-
European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 1: amitriptyline
por: Lampl, Christian, et al.
Publicado: (2023) -
European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention – part 3: topiramate
por: Raffaelli, Bianca, et al.
Publicado: (2023) -
The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis
por: Lampl, Christian, et al.
Publicado: (2023) -
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
por: Sacco, Simona, et al.
Publicado: (2022) -
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
por: Sacco, Simona, et al.
Publicado: (2022)